Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Core Insights - Galapagos NV announced new data from the ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, accepted for oral presentations at two major conferences in June 2025 [1][2][6] Group 1: Study Details - The ATALANTA-1 study focuses on GLPG5101, a second-generation anti-CD19/4-1BB CAR-T product candidate, administered as a single fixed intravenous dose [6][8] - The study evaluates safety, efficacy, and feasibility of decentralized manufacturing of GLPG5101, with 64 patients involved in the oral presentation at EHA [6][8] - The primary objective of the Phase 1 part is to evaluate safety and determine the recommended dose for Phase 2, while the Phase 2 part aims to evaluate the Objective Response Rate (ORR) [8] Group 2: Presentation Information - The EHA presentation will cover low rates of high-grade toxicities associated with GLPG5101 in non-Hodgkin lymphoma patients [4][5] - The ICML presentation will highlight high Complete Response (CR) and Minimal Residual Disease (MRD) negativity rates with GLPG5101, showcasing full results from Cohort 3 [4][5] Group 3: Company Mission and Technology - Galapagos is committed to expanding access to transformative cell therapies for patients with serious hematological and solid tumors, addressing high unmet needs [2][10] - The company utilizes an innovative decentralized cell therapy manufacturing platform, allowing for fresh cell administration within a median vein-to-vein time of seven days [9][10]